According to TipRanks, Matteis is a 5-star analyst with an average return of 16.7% and a 52.83% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, ACADIA Pharmaceuticals, and Alkermes.
In addition to Stifel Nicolaus, Biogen also received a Buy from Truist Financial’s Danielle Brill in a report issued on July 31. However, on the same day, Wedbush assigned a Hold rating to Biogen (NASDAQ: BIIB).
Based on Biogen’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.74 billion and a net profit of $97.5 million. In comparison, last year the company earned a revenue of $2.65 billion and had a net profit of $634.8 million
